darolutamide + docetaxel

**Darolutamide + docetaxel** is a combination therapy of two anticancer drugs: darolutamide, an oral androgen receptor inhibitor, and docetaxel, a chemotherapeutic agent that stabilizes microtubules. This combination is used as part of a triplet regimen, often alongside androgen deprivation therapy (ADT), for the treatment of metastatic hormone-sensitive prostate cancer. Darolutamide works by antagonizing the androgen receptor, thereby inhibiting androgen-driven tumor growth. Docetaxel inhibits cell division by stabilizing microtubules, resulting in apoptosis especially in rapidly dividing tumor cells. Clinical trials demonstrate that the regimen enhances survival and delays disease progression compared to standard therapies. Darolutamide was developed by Orion and Bayer; docetaxel is a widely used chemotherapeutic produced by multiple companies[2][3][5][6].

Other names

darolutamide and docetaxeldarolutamide plus docetaxel